Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Journal of Clinical Oncology2009Vol. 27(12), pp. 2022–2029
Citations Over TimeTop 1% of 2009 papers
Prateek Mendiratta, Elahe A. Mostaghel, Justin Guinney, Alok K. Tewari, Alessandro Porrello, William T. Barry, Peter S. Nelson, Phillip G. Febbo
Abstract
A transcription-based AR signature can detect AR activity within individual prostate cancer specimens and has the potential to help individualize and improve care for patients with CRPC.
Related Papers
- → Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity(2010)64 cited
- → The expression of AURKA is androgen regulated in castration-resistant prostate cancer(2017)58 cited
- → Prostate Cancer Cells Increase Androgen Sensitivity by Increase in Nuclear Androgen Receptor and Androgen Receptor Coactivators; A Possible Mechanism of Hormone-Resistance of Prostate Cancer Cells(2007)50 cited
- → 5α‐androstane‐3α,17β‐diol supports human prostate cancer cell survival and proliferation through androgen receptor‐independent signaling pathways: Implication of androgen‐independent prostate cancer progression(2008)18 cited
- → Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor(2009)12 cited